Articles from QHP Capital

Spectra Medical Devices, LLC (“Spectra”), a portfolio company of QHP Capital, is pleased to announce the closing of its acquisition of XL Precision Technologies Ltd. (“XL-PT”). XL-PT is now a wholly-owned subsidiary of Spectra.

QHP Capital is delighted to announce the appointment of Owen Murray as the new CEO of the combined Bend Bioscience, CoreRx, and Societal entities (the “Company”). Mr. Murray joins us from Aprecia Pharmaceutical, where he served as CEO. With over 25 years of experience in the pharmaceutical and healthcare industries, he brings extensive expertise spanning early product development through commercialization.

QHP Capital, L.P. (“QHP”), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC (“Pro-ficiency” or the “Company”), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy.

QHP Capital (“QHP”), today announced its acquisition of Applied StemCell, Inc. (“ASC” or the “Company”), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products.